Highmark denied your Mounjaro. Here is how to appeal it.

Why Highmark denies Mounjaro

Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes. It is not FDA-approved for weight loss; Zepbound is the weight-management version of tirzepatide. Highmark can cover it under the pharmacy benefit for type 2 diabetes, behind prior authorization and often step therapy. The denials we see most for GLP-1 drugs prescribed off-label for weight loss follow a few patterns:

• Denied as off-label for weight loss. Mounjaro is approved for type 2 diabetes, not weight loss. If it was prescribed mainly for weight management, the plan commonly denies it as not approved for that use. For weight loss, the FDA-approved option is Zepbound.
• Step therapy, metformin first. Many plans require a documented trial of metformin, and sometimes other agents, before they approve a GLP-1. If your records do not show that trial, the claim is denied even when the trial happened.
• Not medically necessary. Highmark frequently applies a blanket 'not medically necessary' designation. A denial often means the submitted records did not, in Highmark's reading, meet the criteria in its medical policy, even when the prescription is appropriate.
• Retrospective reversal after pre-authorization. Highmark has documented authority to reverse a treatment it pre-authorized when it reviews the claim after the fact. If that happened, the timing and the original authorization are both worth raising.
• Formulary tier or quantity limits. Mounjaro may sit on a non-preferred tier or carry a quantity limit. A denial can turn on tier placement rather than your clinical need.

How to win the appeal with Highmark

The pattern that works against Highmark is to use the peer-to-peer review first, and to hold Highmark to its own reviewer-specialty rule.

• Start with a peer-to-peer. Ask your prescriber to request a P2P review with Highmark's medical director before any formal appeal. Highmark reverses a large share of denials at this stage.
• Name the medical policy in writing and answer each criterion in order, with the page of your record that proves it.
• Document the diabetes basis. Attach your type 2 diabetes diagnosis, A1c history, and any prior agents tried, such as metformin, dated, so the request is clearly on-label.
• File within the window. Highmark commercial plans in DE, NY, PA, and WV give you 180 days from the initial denial. If your internal appeal is upheld, you have the right to an external review by an Independent Review Organization.
• Demand a same-specialty reviewer. Highmark's own rules require the clinical peer reviewer to be board-certified in the same or a similar specialty that typically manages your condition. If that did not happen, say so in writing, it is grounds to challenge the denial.

Sources include Highmark's published medical policies and the Mounjaro prescribing information. We cite the specific policy that applies to your plan when we build your appeal.

Highmark + Mounjaro: common questions

Other Mounjaro appeals: Florida Blue · Independence Blue Cross · Aetna · All Mounjaro denials